Press release from Companies
Published: 2024-11-20 08:10:00
Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby announces that the exercise price for the warrants of series TO2 ("TO2"), which were issued in connection with the directed issue and rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO2 has been set to DKK 11.50 per share and the exercise period commences on 21 November 2024.
In September 2024, Curasight carried out both a rights issue and directed issue of units. Through the rights issue and directed issue, 3,683,814 warrants of series TO2 were issued. Each TO2 entitles the holder to subscribe for one (1) new share in Curasight during the exercise period, which runs from and including 21 November 2024 until and including 5 December 2024. The exercise price for TO2 has been set at DKK 11.50 per share. In the event of full utilization of warrants of series TO2, approximately DKK 42.4 million will be added to the Company before issue costs.
Upon full utilization of TO2, the number of shares in Curasight will increase by 3,683,814 shares to a total of 24,366,241 shares and the share capital will increase by DKK 184,190.70 to DKK 1,218,312.05. The dilution at full utilization amounts to approximately 15.1 percent of the capital and votes.
Complete terms and instructions for warrants of series TO2 are available on the Company's website (www.curasight.com). An information sheet containing summary information about the warrant exercise will be available on Curasight (www.curasight.com), Sedermera Corporate Finance AB's (www.sedermera.se) respective websites in connection with the initiation of the exercise period.
Important dates
Advisors
Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
For more information regarding the warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
